Clinical Trial Update: Efficacy Study of Digibind for Treatment of Severe Preeclampsia [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 trial evaluating Digibind for the treatment of severe preeclampsia and presents the trial results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Preeclampsia

Drugs mentioned

• DIGIBIND (digoxin immune Fab)

Snippet

Sponsor: BTG International Inc. | Conditions: Pre-eclampsia | Phase 2 | Status: COMPLETED | Results posted: 2014-08-08